Homology and enzymatic requirements of microhomology-dependent alternative end joining

S Sharma1, SM Javadekar1, M Pandey1, M Srivastava1, R Kumari1 and SC Raghavan*1

Nonhomologous DNA end joining (NHEJ) is one of the major double-strand break (DSB) repair pathways in higher eukaryotes. Recently, it has been shown that alternative NHEJ (A-NHEJ) occurs in the absence of classical NHEJ and is implicated in chromosomal translocations leading to cancer. In the present study, we have developed a novel biochemical assay system utilizing DSBs flanked by varying lengths of microhomology to study microhomology-mediated alternative end joining (MMEJ). We show that MMEJ can operate in normal cells, when microhomology is present, irrespective of occurrence of robust classical NHEJ. Length of the microhomology determines the efficiency of MMEJ, 5 nt being obligatory. Using this biochemical approach, we show that products obtained are due to MMEJ, which is dependent on MRE11, NBS1, LIGASE III, XRCC1, FEN1 and PARP1. Thus, we define the enzymatic machinery and microhomology requirements of alternative NHEJ using a well-defined biochemical system.

Cell Death and Disease (2015) 6, e1697; doi:10.1038/cddis.2015.58; published online 19 March 2015

DNA double-strand breaks (DSBs) are the most deleterious to the genome among various lesions. Nonhomologous end joining (NHEJ) is one of the major DSB repair pathways in higher eukaryotes.1–3 In the absence of key NHEJ factors, another distinct but error-prone pathway known as alternative NHEJ (A-NHEJ) has been described to have an important role in DSB repair.4–7 It has been shown that majority of A-NHEJ mediated repair of DSBs utilize distinct microhomology regions, hence termed microhomology-mediated end joining (MMEJ).4,8,9

A-NHEJ has been proposed as a possible cause for chromosomal translocations. Studies have shown co-amplification of c-MYC and IgH locus from pro-B lymphomas in mice deficient for p53 and NHEJ.10 A reduced level of class switch recombination (CSR) and increased number of chromosomal rearrangements at IgH locus have been shown in XRCC4- and LIGASE IV-deficient murine B cells.8 The occurrence of robust alternative end joining has been established in the absence of NHEJ proteins, when murine RAG proteins were absent.11

Unraveling the enzymatic machinery involved in alternative end joining is currently an active area of research. Recently, it was shown that MRE11-RAD50-NBS1 complex may be involved in a subset of alternative NHEJ.5,12–14 whereas ATM has a regulatory role.15 Role of PARP1 in repairing switch regions through a microhomology-mediated pathway leading to IgH/c-MYC translocations during immunoglobulin CSR has been described.16 Besides, studies have also suggested a role for DNA LIGASE II and WRN in A-NHEJ.17 Interestingly, XRCC1 was shown to be dispensable in A-NHEJ during CSR, whereas functional relevance of Ligase I, III and Pol λ have been established.18–20 Hence, it can be concluded that canonical NHEJ (C-NHEJ) requires LIGASE IV–XRCC4 complex, while A-NHEJ is predominant in the absence of C-NHEJ proteins and is mainly characterized by joining utilizing microhomology (MMEJ). Further, it has been demonstrated that RPA, when bound to single-stranded DNA can antagonize MMEJ.21 Very recently, a genetic system was reported in budding yeast to detect microhomology-mediated repair.22 However, little is known whether alternative NHEJ can be operative when classical NHEJ machinery is intact.23 A recent study suggested that MMEJ is also functional in normal mammalian cells. Besides, HR and MMEJ share the initial steps of end resection for DSB repair in mammalian cells.24 However, it appears that there is not much consensus among different research groups over its presence and relevance in normal cells.25 Therefore, several aspects of alternative NHEJ still need to be resolved. For example, its precise mechanism and microhomology length requirements are yet to be fully uncovered. Its occurrence in normal cells needs to be proved beyond doubt. Although there are independent studies showing the role of multiple proteins using gene knockdown or knockout strategies, their involvement needs to be confirmed.

In the present study, we have established a cell-free repair assay system using which we show that MMEJ is operative even in the presence of classical NHEJ machinery. Further, our data suggest that MMEJ operates not only in cancer cells but also in normal cells. We show that a minimum of 5 nt microhomology is required for MMEJ and is independent of classical NHEJ proteins such as KU70, KU80 and LIGASE IV. Finally, we show that MRN complex, XRCC1, FEN1, PARP1 and LIGASE III are the factors responsible for joining mediated through microhomology.

1Department of Biochemistry, Indian Institute of Science, Bangalore 560012, India
2Corresponding author: SC Raghavan, Department of Biochemistry, Indian Institute of Science, Malleshwaram, Bangalore 560012, India. Tel: +91 80 2293 2674; Fax: +91 80 2360 0814; E-mail: sathees@biochem.iisc.ernet.in

Abbreviations: CSR, class switch recombination; NHEJ, nonhomologous DNA end joining; DSB, double-strand break; MMEJ, microhomology-mediated end joining; C-NHEJ, classical nonhomologous DNA end joining; A-NHEJ, alternative nonhomologous DNA end joining; ATP, adenosine triphosphate; IP, immunoprecipitation

Received 27.5.14; revised 24.12.14; accepted 09.2.15; Edited by R Aqeilan
Results

A cell-free system to study backup NHEJ pathway. Biochemical assay systems are used as ideal tools for characterizing DNA repair pathways. In the present study, we have used an in vitro approach utilizing a cell-free system to biochemically characterize the mechanism of microhomology-mediated alternative NHEJ.

The steps involved in assaying MMEJ are outlined (Figure 1a). Two double-stranded oligomers of different lengths, containing 10 (or 22) nt microhomology were designed such that joining by utilizing microhomology results in shortening of the product (62 or 76 nt), which can be detected using radioactive PCR (Figures 1b and c). Similarly, joining by C-NHEJ could result in reaction products of varying sizes. In order to optimize assay conditions for MMEJ, various parameters were tested. Increasing concentrations of rat testicular extracts were incubated with DNA substrates containing 10 nt microhomology for 2 h, heat inactivated, PCR amplified using radiolabelled primers and resolved on 8% denaturing polyacrylamide gel. Results showed efficient MMEJ (62 nt) from 200 ng protein onwards, whereas C-NHEJ (~97 nt) was detectable only at protein concentration of 500 ng onwards (Figure 2a). Time kinetics analysis showed MMEJ and C-NHEJ from 5 min onwards. Interestingly, kinetics of C-NHEJ was faster compared with MMEJ (Figure 2b). Besides, testicular extracts showed optimum MMEJ at 30 °C, the physiological temperature (Figure 2c). An enhancement in the efficiency of MMEJ was observed with an increase in concentrations of Mg²⁺, a co-factor, optimum being 10 mM (Figure 2d). Efficiency of MMEJ was maximum at 0.5 mM adenosine triphosphate (ATP; Figure 2e). Sensitivity of MMEJ assay was determined by serially diluting DNA and detecting the joining from 100 pM onwards, which exponentially increased till 4 nM (Supplementary Figure 1). Thus, we were successful in establishing a cell-free repair assay system to study MMEJ.

MMEJ in normal and cancer cells. In order to investigate MMEJ in normal tissues, cell-free extracts were prepared from rat testes and thymus and used for cell-free DSB repair assay. Double-stranded DNA containing microhomology were incubated in extracts (normal tissues and cancer cells, for 2 h at 30 °C; Figures 3a–d). Results showed detectable MMEJ in both normal tissues and cancer cell lines. MMEJ was more prominent in testes compared with thymus among normal tissues (Figures 3a–d). Upon comparing the relative intensities of MMEJ products with input DNA substrates, results indicated that 2–3% of DNA molecules would have joined using microhomology in different cellular extracts (Figure 3d). Besides MMEJ, we could detect joining due to C-NHEJ despite using substrates that promote microhomology-mediated joining (Figures 3c and d). Interestingly, varying levels of MMEJ were observed in other normal tissues such as spleen, lungs, heart, liver and kidney (Supplementary Figure 2). Thus, our study revealed an efficient MMEJ in normal tissues.

Figure 1  Schematic presentation of cell-free repair assay to evaluate microhomology-mediated alternative DNA end joining. (a) Outline of experimental strategy used for detection of MMEJ. Two double-stranded oligomers possessing 10 nt microhomology were incubated with buffer and cell-free extracts. After heat inactivation, end-joined products were subjected to radioactive PCR and the products were resolved on 8% denaturing polyacrylamide gel. (b and c) Schematic showing strategy used for detection of alternative NHEJ products using radiolabelled oligomers. Examples of 10 nt (b) and 22 nt (c) microhomology-bearing DNA substrates are depicted to show strategy employed for detection of MMEJ. Dark rectangles indicate positions of microhomology. PCR primer positions are also indicated.
Cloning and sequencing of end-joined junctions from independent biological repeats revealed that MMEJ could take place in both normal and cancer cells by utilizing microhomology (Figure 3e, Supplementary Figure 3). End-joined junctions were also due to C-NHEJ, which was characterized by small deletions or insertions (Figure 3e, Supplementary Figure 3). These results confirmed the occurrence of microhomology-mediated joining in normal cells. Western blot analysis showed efficient expression of RAD50, MRE11, ATM, PARP1, LIGASE IV and LIGASE III in all four cell types (Figure 3f). Besides, we observed varying expression of APLF, BRCA1, WRN and LIGASE I in normal and cancer cells (Figure 3f).

Role of microhomology in alternative end joining. In order to understand the extent of microhomology required for MMEJ, oligomeric DNA containing DSBs flanked by various lengths of microhomology (3, 5, 8, 10, 13, 16, 19 or 22 nt) were designed and synthesized in such a way that following MMEJ, a restriction enzyme site would be generated to understand the extent of microhomology required for MMEJ. Oligomeric DNA containing DSBs flanked by various lengths of microhomology (3, 5, 8, 10, 13, 16, 19 or 22 nt) were designed and synthesized in such a way that following MMEJ, a restriction enzyme site would be generated.

Characterization of microhomology-mediated end joining
S Sharma et al

Cloning and sequencing of end-joined junctions from independent biological repeats revealed that MMEJ could take place in both normal and cancer cells by utilizing microhomology (Figure 3e, Supplementary Figure 3). End-joined junctions were also due to C-NHEJ, which was characterized by small deletions or insertions (Figure 3e, Supplementary Figure 3). These results confirmed the occurrence of microhomology-mediated joining in normal cells. Western blot analysis showed efficient expression of RAD50, MRE11, ATM, PARP1, LIGASE IV and LIGASE III in all four cell types (Figure 3f). Besides, we observed varying expression of APLF, BRCA1, WRN and LIGASE I in normal and cancer cells (Figure 3f).

Role of microhomology in alternative end joining. In order to understand the extent of microhomology required for MMEJ, oligomeric DNA containing DSBs flanked by various lengths of microhomology (3, 5, 8, 10, 13, 16, 19 or 22 nt) were designed and synthesized in such a way that following MMEJ a restriction enzyme site would be generated.

Figure 2 Evaluation of different experimental conditions for the development of a cell-free repair system to assess microhomology-mediated alternative DNA end joining. (a) Evaluation of MMEJ in presence of increasing concentrations of cell-free extracts. Testicular extracts (0, 0.025, 0.050, 0.075, 0.1, 0.2, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5 and 3.0 μg) were incubated with DNA substrates (4 nM) 10 nt microhomology for 2 h at 30 °C. Lane 1 indicates no protein control. Lanes 2–7 indicate MMEJ in the presence of 0, 0.1, 0.25, 0.5, 1, 2 and 4 mM of MgCl2, respectively. (b) Time kinetics of MMEJ on a 10-nt microhomology-containing DNA substrates in rat testicular extracts for 2 h at 4, 16, 25, 30, 37 and 40 °C. Lane 1 indicates no protein control. (c) Effect of ATP on MMEJ catalyzed by cell-free extracts. Rat testicular extracts (1 μg) were incubated with microhomology substrates and increasing concentrations of ATP for 2 h. Lanes 2–7 indicate MMEJ in the presence of 0, 0.1, 0.25, 0.5, 1, 2 and 4 mM of ATP, respectively. In panels a–e, bar diagram showing quantification based on at least three independent experiments are provided. MMEJ products are indicated by an arrow, while C-NHEJ products are bracketed. In each case, lower panel serves as the loading control for equal DNA, indicated as ‘input DNA’. M and M indicate 60 nt marker and 50 nt ladder, respectively. PSLU in y axis of bar diagram indicates photostimulated luminescence units. *P<0.05; **P<0.01; ***P<0.001. Error bars represent S.E.M.
Characterization of microhomology-mediated end joining
S Sharma et al

Figure 3: Comparison of frequency and mechanism of MMEJ between normal and cancer cells. (a) SDS-PAGE profile of cell-free extracts prepared from testis, thymus, K562 and Reh. (b) Bar diagram showing densitometry analysis for proteins in PAGE shown in panel a. (c) Comparison of MMEJ and C-NHEJ efficiency catalyzed by testis, thymus, K562 and Reh cell-free extracts. Cell-free extracts (1.0 μg) were incubated with oligomeric DNA possessing 10 nt microhomology in a buffer containing 10 mM Tris-HCl (pH 8.0), 20 mM MgCl₂, 1 mM ATP, 10% PEG 8000 and 1 mM DTT for 2 h at 30 °C. The products were resolved on a PAGE and visualized. For other details refer Figure 2 legend. M is 50 nt ladder. M is marker for 60 nt position. MMEJ and NHEJ products are indicated. (d) Bar diagram showing comparison of MMEJ and C-NHEJ catalyzed by testis, thymus, K562 and Reh, relative to input. *P<0.05. Error bars represent S.E.M. (e) Comparison of different modes of NHEJ among normal tissues and cancer cell lines. The total end-joining junctions from testis, thymus, K562 and Reh cells were PCR amplified, cloned and sequenced. Each sequence shown is derived from an independent clone. Cases where microhomology is used are indicated in the column. The 'joined products' indicate the usage of substrates. Red color indicates sequences that are deleted, while blue indicates insertions. Green indicates mutations in the sequence. Microhomology region is underlined and the sequence is indicated in bold. (f) Western blots showing expression profile of canonical and noncanonical NHEJ proteins in testis, thymus and leukemic cell lines. Bands marked with an asterisk could be an isoform. Both isoforms of Ligase III, α and β, are indicated. PCNA and actin were used as loading control.

Similarly, bands corresponding to ~60 and 65 nt in 8 and 13 nt microhomology substrates were digestible with XmrL and XcmL, respectively (Supplementary Figure 4b). Besides, we could not find any specific band, which was sensitive to NotI digestion when 3 nt microhomology substrate was used (Supplementary Figure 4b). As there was no suitable restriction enzyme site, we could not perform similar analysis for substrates containing 10 nt microhomology. These findings suggest that MMEJ protein machinery recognizes microhomology regions to undergo end joining. Furthermore,
a microhomology length of more than 3 nt is essential for its operation.

Comparison of MMEJ in thymic cell-free extracts showed an increase in the efficiency of joining with an increase in length of microhomology (data not shown). Similar to testicular extracts, we could not detect any joining due to MMEJ, in case of 3 nt microhomology-containing DNA substrates. MMEJ was observed in K562 and Reh cell-free extracts, when substrate containing as low as 5 nt microhomology was used (Figure 4c and data not shown). Further, a definitive enhancement in the MMEJ efficiency was observed with an increase in length of microhomology (Figure 4c and data not shown). Further, we could find an overall decrease in the efficiency of joining when 3 nt microhomology-containing substrate was used (Figure 6b).

In order to confirm the identity of potential MMEJ products, corresponding bands were excised, purified and subjected to DNA sequencing for 3, 5, 8, 10, 13, and 16 nt microhomology-containing substrates. Results confirmed the presence of MMEJ in case of each substrate, when the microhomology was 8 nt or more (Figure 5a). In case of 5 nt microhomology substrates, only few junctions utilized microhomology (based on restriction digestion analysis), whereas majority of the joining was through C-NHEJ. In case of 3 nt microhomology substrates, none of the clones showed usage of microhomology. Unlike C-NHEJ, MMEJ junctions did not show any insertions, although point mutations were rarely seen. Similar results were also seen when MMEJ junctions were sequenced from thymus (Figure 5b). These results suggest that the MMEJ is dependent on the length of microhomology region.

MMEJ is not dependent on classical NHEJ proteins. As we could distinguish MMEJ products using cell-free repair system, we were interested in protein machinery responsible for alternative NHEJ. To begin with, possible involvement of C-NHEJ proteins like KU70, KU80 and LIGASE IV was tested by immunoprecipitation (IP) (Figure 6a) followed by joining assay. No effect on MMEJ products (10 and 19 nt microhomology) was observed when immunodepleted extracts of KU70, KU80 and LIGASE IV were used (Figure 6b). However, a significant decrease in the efficiency of C-NHEJ products was observed. Further, we could find an overall decrease in the efficiency of joining when 3 nt microhomology-containing substrate was used (Figure 6b).

In all cases, reaction products due to joining through NHEJ were also seen (Figure 4a). However, a significant decrease in the efficiency of C-NHEJ products was observed. Further, we could find an overall decrease in the efficiency of joining when 3 nt microhomology-containing substrate was used (Figure 6b). Consistent with these findings, when cell-free extracts were prepared from LIGASE IV knockout cells, there was no reduction in MMEJ efficiency, whereas C-NHEJ was significantly inhibited (Figure 6c). Besides, immunodepletion of POL μ or POL λ also did not result in any significant reduction in the efficiency of MMEJ, whereas levels of NHEJ products were substantially reduced (Figure 6d).
observed, which could be attributed to the ability of wortmannin to inhibit other PI 3-kinases (Figure 6e). Inhibition of C-NHEJ along with an increase in MMEJ could be observed with 19 nt microhomology substrate upon treatment with wortmannin (Supplementary Figure 5). Thus, this result, in conjunction with above findings, suggests that MMEJ is not dependent on classical NHEJ proteins.

In order to test whether the results obtained using the cell-free repair system are relevant at the cellular level, siRNA-mediated knockdown of C-NHEJ proteins was performed. siRNA against KU70, KU80, XRCC4 or LIGASE IV were transfected in Reh cells and cell-free extracts were prepared along with scrambled siRNA control. Knockdown of respective protein was confirmed by western blotting (Figure 6f). When these cell-free extracts were used for MMEJ assay on substrates with DSBs flanked with 3, 10 and 19 nt microhomology, an overall reduction in the efficiency of joining of 3 nt microhomology substrate was observed (Figure 6g). In contrast, substrates possessing 10 and 19 nt microhomology, showed improved efficiency of MMEJ upon knockdown of KU70, KU80, XRCC4 or LIGASE IV (Figure 6g). As expected, C-NHEJ products exhibited a remarkably low efficiency of joining (Figure 6g). Hence, siRNA knockdown within the cells in conjunction with immunodepletion studies suggest that C-NHEJ proteins are not involved during MMEJ.

Microhomology-mediated alternative NHEJ is dependent on other repair proteins. As MMEJ is independent of C-NHEJ proteins, we were interested in identifying the proteins involved in MMEJ. On the basis of previous studies, we selected candidate protein targets for the study. Immunodepletion of XRCC1, PARP1 and LIGASE I was performed from rat testicular extracts (Figure 7a) and used for MMEJ on a 10-nt microhomology substrate. Interestingly, results showed a significant decrease in the efficiency of MMEJ, whereas C-NHEJ remained same in case of XRCC1-, LIGASE I- and PARP1-immunodepleted extracts as compared with that of control (Figure 7b). This suggests that MMEJ utilizes protein machinery consisting of XRCC1, LIGASE I and PARP1.

Figure 5  Sequence analysis of MMEJ junctions, when DSBs with different microhomology regions were used. Products due to possible MMEJ (3, 5, 8, 10, 13 and 16 nt microhomology) catalyzed by testicular and thymic extracts were gel purified, cloned and sequenced. The sequences denoted in red color are the deleted nucleotides. (a) MMEJ junctions from rat testicular extracts. (b) MMEJ junctions derived from rat thymic extracts. For other details, refer Figures 1 and 4 legends.

| Substrate | No. of junctions | micro-Homology |
|-----------|------------------|----------------|
| 3 nt      | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 1 3 |
| 5 nt      | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 3 8 |
| 8 nt      | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 3 0 |
| 10 nt     | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 1 2 |
| 13 nt     | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 1 4 |
| 16 nt     | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 3 8 |
| 3 nt      | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 3 0 |
| 5 nt      | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 1 2 |
| 8 nt      | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 1 4 |
| 10 nt     | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 3 8 |
| 13 nt     | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 3 0 |
| 16 nt     | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 1 2 |
| 3 nt      | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 3 8 |
| 5 nt      | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 3 0 |
| 8 nt      | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 1 2 |
| 10 nt     | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 1 4 |
| 13 nt     | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 3 8 |
| 16 nt     | gagaCATGGCGAGTCGGCTCAGTGATCGG...tgag-3' | 1 2 |

Figure 5  Sequence analysis of MMEJ junctions, when DSBs with different microhomology regions were used. Products due to possible MMEJ (3, 5, 8, 10, 13 and 16 nt microhomology) catalyzed by testicular and thymic extracts were gel purified, cloned and sequenced. The sequences denoted in red color are the deleted nucleotides. (a) MMEJ junctions from rat testicular extracts. (b) MMEJ junctions derived from rat thymic extracts. For other details, refer Figures 1 and 4 legends.
Characterization of microhomology-mediated end joining
S Sharma et al

Mmirin inhibits MRE11, an enzyme involved in homologous recombination and suggested to have a potential role in A-NHEJ. Testicular extracts were incubated with increasing concentrations of mirin (100, 200, 400, 600, 800 and 1000 μM) and used for MMEJ reaction with 3, 10 and 19 nt microhomology substrates. Results showed reduction in the formation of MMEJ products with increasing concentrations of mirin, whereas its effect on NHJ was minimal (Figure 7c), except at higher concentrations, which could be attributed to nonspecificity. These results indicate the possible involvement of MRN complex in MMEJ.

siRNA-mediated knockdown was performed in Reh cells to evaluate the role of MRE11, RAD50, NBS1, PARP1, FEN1, ARTEMIS and LIGASE IV in MMEJ in physiological context. Cell-free extracts were prepared from experimental and scrambled siRNA-treated cells. Following confirmation of the knockdown by western blotting (Figure 7d), MMEJ assay was carried out on substrates harboring 3, 10 or 19 nt microhomology. Results showed a distinct reduction in MMEJ when MRE11, NBS1, LIGASE III, PARP1 expressions were knocked down in case of substrates possessing 10 and 19 nt microhomology (Figure 7e). Interestingly, inhibition of RAD50 expression did not result in significant reduction in MMEJ in case of 10 nt microhomology-containing substrate (Figure 7f). However, we did not observe any significant difference in the efficiency of C-NHEJ products upon knockdown of these proteins.

Figure 6 Evaluation of the effect of C-NHEJ proteins on joining of DNA substrates containing DSBs flanked with 3, 10 and 19 nt microhomology regions. (a) Western blots showing immunodepletion of KU70, KU80 and LIGASE IV proteins from rat testicular cell extracts. Control is whole cell extract and IP is immunodepleted extract. GAPDH was used as an internal loading control. (b) Efficiency of MMEJ and NHEJ following immunodepletion of KU70, KU80 and LIGASE IV on DNA substrates containing 3, 10 and 19 nt microhomology. (e) Comparison of MMEJ and C-NHEJ in NALM6 and Ligase IV genetic knockout cell lines. Cell-free extracts were incubated with increasing concentrations of mirin (100, 200, 400, 600, 800 and 1000 μM) and evaluated for MMEJ efficiency using the immunodepleted extracts. (d) Western blots showing immunodepletion of polymerase μ and ι and evaluation of MMEJ efficiency using the immunodepleted extracts. (e) Effect of wortmannin, a DNA-PKcs inhibitor on MMEJ. Wortmannin (1, 10 and 100 μM) was incubated with cell-free extracts of testis (2 μg) and oligomeric DNA containing 10 nt microhomology and analyzed. In panels b-e, MMEJ products are indicated by arrow, while NHJ products are bracketed. (f) siRNA-mediated knockdown of classical NHEJ proteins in Reh cells. Reh cells were transfected with siRNA against KU70, KU80, XRCC4 and LIGASE IV and harvested after 48 h. Cell-free extracts were prepared and efficiency of knockdown was evaluated by Western blotting and was quantified (shown as bar diagram). Scrambled siRNA was used as control. (g) Efficiency of MMEJ and NHEJ following siRNA-mediated knockdown of expression of KU70, KU80, XRCC4 and LIGASE IV. MMEJ products are boxed, while NHJ products are bracketed. M is marker.
been suggested to repair DSBs using microhomology, a DNA-PK- and/or KU-independent alternative pathway has been proposed for repairing various types of DSBs. Recently, a DNA-PK- and PARP1-dependent pathway has been suggested to repair DSBs using microhomology, and to be responsible for deletions and chromosomal translocations. Microhomology-mediated joining is a major form of alternative NHEJ and has been suggested to operate in cells that are deficient in C-NHEJ. Microhomology-mediated joining is dependent on microhomology and occurs in normal cells. In the present study, we have established a biochemical system to study MMEJ. By using such a system, we are able to detect MMEJ even in normal cells, when DSBs flank the microhomology regions.

MMEJ is dependent on microhomology and occurs in normal cells. In the present study, we have established a biochemical system to study MMEJ. By using such a system, we are able to detect MMEJ even in normal cells, when DSBs flank the microhomology regions.

Previously, we have shown that efficiency and mode of DSB joining is dependent on DNA end configurations. In the...
present study, when DNA possessing different microhomology (3–22 nt) were used, a length of 3 nt microhomology was insufficient to recruit MMEJ machinery; instead C-NHEJ was preferred. Importantly, a 5-nt microhomology was sufficient to elicit MMEJ consistent with the earlier results. However, MMEJ efficiency was improved when longer microhomology was present. Class switch recombination occurs at 20–50% of the stimulated cells and several joining junctions use longer microhomology in C-NHEJ-deficient B cells. Preferential joining using 7 nt microhomology was reported in KU80- and XRCC4-deficient cells. Therefore, length of microhomology is one of the factors that determine the recruitment of the protein machinery for MMEJ. Previously, plasmid-based biochemical assay systems were used to study backup NHEJ pathways using cell lines deficient for DSB repair proteins.

MMEJ utilizes specific protein machinery and can coexist along with C-NHEJ. Our results showed that in physiological scenario, the set of proteins required for C-NHEJ and MMEJ are distinct. Specifically, during MMEJ, following the end resection, microhomology regions are aligned in such a way that intact product formation takes place following processing of the flap region and ligation. On the basis of our studies, it appears that the efficiency of joining by MMEJ is particularly more favorable when the substrates possess ends with microhomology, hence exhibiting lower efficiency by C-NHEJ. Besides, based on the studies from our group and others, it appears that there is a complete set of proteins that can perform MMEJ. In the physiological context, when some of the ends are left unrepaired, it is possible that this repair machinery takes over the process to repair such DNA ends. However, other than microhomology, the additional factors contributing toward the selection of such alternative pathway, within cells, are yet to be understood. Mutation in one of the C-NHEJ proteins alone may not be solely responsible. Recently, MMEJ has been described as the repair mechanism involved in generation of chromosomal translocations. The fact that many such rearrangements are reported in remarkably higher frequency in healthy individuals further confirm that alternative pathway of NHEJ might be operating in normal scenario as well. It is well known that the first hit of genetic alterations like chromosomal translocations and deletions, which lead to carcinogenesis, occur in noncancerous cells. Thus, our observations of MMEJ in normal cells are of great importance.

Microhomology-mediated alternative NHEJ is dependent on MRE11, NBS1, PARP1 and LIGASE III/XRCC1 complex. By using both immunodepletion along with inhibitor studies in cell-free extracts and siRNA-mediated knockdown within the cells, we deciphered that classical NHEJ proteins are not required for microhomology-mediated alternative NHEJ (Figure 8). Instead, we found that proteins such as PARP1, XRCC1, LIGASE III, MRE11, FEN1 and NBS1 are important for MMEJ (Figure 8). As MRN complex has an end resection property, it searches for homology and once aligned, DSBs are joined using LIGASE III/XRCC1. Alternatively, it is possible that a yet unidentified protein recognizes the microhomology region and recruits MRN complex or PARP proteins to the site of repair. Role of MRE11 in alternative NHEJ has been shown earlier. Here we observed a significant reduction in the intensity of MMEJ product and a slight reduction in C-NHEJ products upon removal of MRN complex in case of substrates containing either 10 or 19 nt microhomology. Earlier studies have shown that depletion or inhibition of MRE11 reduces end joining in wild-type and XRCC4-/- cells showing that MRE11 promotes both C-NHEJ and MMEJ. Studies have also shown the potential role of PARP1 and DNA LIGASE III in alternative pathway of NHEJ using in vivo plasmid rejoining assay. DNA LIGASE III as a candidate component of backup end joining was suggested by fractionation studies using plasmid rejoining assay. Further, it has been shown that involvement of XRCC1–LIGASE III was independent of DNA-PK and XRCC4–LIGASE IV.

Hence, our study establishes a well-defined biochemical system for the characterization of microhomology-mediated alternative NHEJ. It opens a new window to understand the relative frequency of classical NHEJ and MMEJ under physiological conditions. It might also help to interpret the physiological conditions where one pathway may be chosen over the other while repairing DNA DSBs, which could further help in understanding the generation of chromosomal translocations leading to cancer.

Materials and Methods
Enzymes, chemicals and reagents. Chemical reagents were obtained from Sigma Chemical Co. (St Louis, MO, USA), Amresco (Solon, OH, USA), SRL (Mumbai, India) and Himedia (Mumbai, India). DNA-modifying enzymes were from New England Biolabs (Beverly, MA, USA) and antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Radiolabelled nucleotides were purchased from BRIT (Hyderabad, India).

Preparation of DNA substrates for MMEJ. Oligomers containing appropriate microhomology regions were designed and commercially synthesized (Supplementary Table 1). The oligomers were then purified on denaturing polyacrylamide gels as described. In order to generate double-stranded oligomeric DNA containing DSBs with flanking microhomology regions, complementary oligomers were annealed in 100 mM NaCl and 1 mM EDTA as described. Length of microhomology region used in the study is 3, 5, 8, 10, 13, 16, 19 and 22 nt (Supplementary Table 2). The 5' end labelling (γ²³²P) ATP of the SS60 and other oligomers was done using T4 polynucleotide kinase as described previously and stored at −20°C.

Preparation of cell-free extracts from tissues and cell lines. Cell-free extracts were prepared from testes and thymus of male winstar rats (3–4 weeks), as described earlier. Extracts were aliquoted and stored at −80 °C till use. Protein concentration was determined by Bradford's assay. Protein amount was normalized further by loading on SDS polyacrylamide gel, followed by staining with Coomassie Brilliant Blue.

Cell-free extracts from cell lines K562 (human immortalized myelogenous leukemia line) and Reh (acute lymphocytic leukemia line) were prepared as described. Briefly, cells were washed with PBS followed by washing in hypotonic lysis buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA and 5 mM DTT). Cells were resuspended in 100 μl of hypotonic buffer followed by homogenization after 20 min, and protease inhibitors were added (phenylmethylsulfonyl fluoride, 0.01 M; aprotinin, 2 μg/ml; pepstatin, 1 μg/ml; leupeptin, 1 μg/ml). After 20 min on ice, 50 μl of high-salt buffer (50 mM Tris-HCl (pH 7.5), 1 M KCl, 2 mM EDTA and 2 mM DTT) was added, and the extract was centrifuged for 3 h at 42 000 r.p.m. at 4°C in a Beckman TL-100 Rotor (Beckman, Palo Alto, CA, USA). The supernatant was dialyzed overnight against dialysis buffer (20 mM Tris-HCl (pH 8.0), 0.1 M KOAc, 20% glycerol, 0.5 mM EDTA and 1 mM DTT), snap frozen and stored at −80°C.
Evaluation of MMEJ. DNA end joining assay was performed by incubating 4 mM of radiolabelled oligomeric DNA containing microhomology in cell-free extracts (1 μl), unless specified otherwise (testicular cells) in a buffer (10 mM Tris-HCl (pH 8.0), 20 mM MgCl₂, 1 mM ATP, 10% PEG 8000, and 1 mM DTT) in a reaction volume of 20 μl at 30 °C for 2 h or as specified (Figure 1a). End-joining reactions were arrested by heat inactivation of proteins at 65 °C for 20 min. Products were detected by gel electrophoresis and visualized by autoradiography. The quantity of input DNA in the PCR reaction was determined by the amplification of the longer MMEJ substrates using primers (MS143 and MS144), which served as internal loading controls. The blots were developed using chemiluminescent antibodies as per standard protocol. TUBULIN, GAPDH, PCNA or ACTIN were used as internal loading controls. The blots were developed using chemiluminescent solution (Immobilon Western, Millipore) and scanned by gel documentation system (LAS 3000, Fuji, Shizuoka, Japan).

Cloning and sequencing of end-joined junctions. For cloning of total reaction products, PCR was performed using primers S560 and S561. For cloning of prospective MMEJ products, the band of interest was excised and purified from the gel and used for PCR amplification using the same set of primers. In all cases, PCR products were purified and cloned into TA vector as described. The presence of insert was confirmed by restriction enzyme digestion followed by DNA sequencing (SoGenom Labs Pvt Ltd., Cochin, India).

siRNA transfection. Reh cells were used for siRNA transfection studies. Briefly, Reh cells (2.5 × 10⁶) were transfected with a cocktail of siRNA against KU70, KU80, XRCC4, LIGASE IV, MRE11, RAD50, NBS1, PARP1 or LIGASE III using oligofectamine as described earlier. The cells were harvested after 48 h and cell-free extracts were prepared as described above. The efficiency of knockdown was confirmed using immunoblotting and used for assessing DNA end joining.

Immunoblotting and IP. For immunoblotting analysis, 20–40 μg of protein was resolved on 7–10% SDS polyacrylamide gel. Following electrophoresis, proteins were transferred to PVDF membrane (Millipore, Billerica, MA, USA), and probed with appropriate primary antibodies against KU70, KU80, XRCC4, LIGASE IV, POL μ, POL λ, POL θ, MRE11, WRN, CTIP, APLF, PARP1, BRCA1, RAD50, NBS1, LIGASE I and LIGASE III (Santa Cruz Biotechnology) and appropriate secondary antibodies as per standard protocol. TUBULIN, GAPDH, PCNA or ACTIN were used as internal loading controls. The blots were developed using chemiluminescent solution (Immobilon Western, Millipore) and scanned by gel documentation system (LAS 3000, Fuji, Shizuoka, Japan).

Figure 8 Mechanism of microhomology-mediated alternative NHEJ. Schematic presentation shows different modes of DSB repair via NHEJ and MMEJ. When a DSB is generated flanking a microhomology region, there are two outcomes. If KU proteins bind to the ends and recruit C-NHEJ proteins, it can result in C-NHEJ. Alternatively, if the microhomology is recognized by MRN complex and PARP1 or a yet unidentified protein, it can follow MMEJ. This is followed by recruitment of FEN1/unknown endonucleases, which can remove the flap. Further, recruitment of XRCC1–LIGASE III at the site helps in ligating the DNA ends leading to an intact DNA.

Characterization of microhomology-mediated end joining
S Sharma et al

Cell Death and Disease
Sallmyr A, Tomkinson AE, Rassool FV. Up-regulation of WRN and DNA ligase IIIα in
16. Robert I, Dantzer F, Reina-San-Martin B. Parp1 facilitates alternative NHEJ, whereas Parp2
18. Han L, Mao W, Yu K. X-ray repair cross-complementing protein 1 (XRCC1) deficiency
et al.
19. Bussolati B, Scarpa A, Romani A, et al. X-chromosome inactivation. Cell 2001; 106:
20. Crespam E, Czabary T, Maga G, Hubscher U. Microtomohydro-methylated DNA strand annealing and elongation by human DNA polymerases lambda and beta on normal and repetitive DNA sequences. Nucleic Acids Res 2012; 40: 5577–5590.
21. Deng SK, Gibb B, de Almeida MJ, Greene EC, Symington LS. RPA antagonizes microtomohydro-methylated repair of DNA double-strand breaks. Nat Struct Mol Biol 2014; 21: 405–412.
22. Villarreal DD, Lee K, Deem A, Shim EY, Malkova A, Lee SE. Microtomohydro directs diverse DNA break repair pathways and chromosomal translocations. PLoS Genet 2012; 8: e1003025.
23. Paterson NI, Li S, Wasanabe G, Lieber MR. Non-homologous and jointing often uses microtomohydro: implications for alternative end joining. DNA Repair 2014; 17: 74–80.
24. Truong LN, Li Y, Shi LZ et al. Microtomohydro-methylated end joining and homologous recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells. Proc Natl Acad Sci USA 2013; 110: 7720–7725.
25. Wanner P, West SC. DNA end-joining catalyzed by human cell-free extracts. Proc Natl Acad Sci USA 1998; 95: 14066–14070.
26. Chen X, Zhong S, Zhu X, Dizeguela B, Eilenberger T, Wilson GM et al. Racial definition of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res 2008; 68: 3169–3177.
27. Rak A, Boyer-Chatenet L, Sattier RM, Moçi AP, Lee JH, Nicollèt ML et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol 2008; 4: 119–125.
28. Nussenzwag A, Nussenzwag MC. Origin of chromosomal translocations in lymphoid cancer. Cell 2010; 141: 27–38.
29. Nambiar M, Raghavan SC. How does DNA break during chromosomal translocations? Nucleic Acids Res 2011; 39: 5813–5825.
30. Bennardo N, Cheng A, Huang N, Stark JM. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet 2008; 4: e1000110.
31. Sharma S, Choudhary B, Raghavan SC. Efficiency of nonhomologous DNA end joining varies among somatic tissues, despite similarly in mechanism. Cell Mol Life Sci 2011; 68: 661–676.
32. Kobayashi EB, Gomelsky L, Han JO, Stamato RD, Roth DB. Double-strand break repair in Ku80- and XRC4-deficient cells. Nucleic Acids Res 1998; 26: 3333–3342.
33. Wang H, Perrault AR, Takeda Y, Qin W, Ilias G. Biochemical evidence for Ku-independent DNA repair pathways of NHEJ. Nucleic Acids Res 2003; 31: 3377–3383.
34. Wang M, Wu W, Rosidi B, Zhang L, Wang H, Ilias G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 2006; 34: 6170–6182.
35. Wang H, Rosidi B, Perrault R, Wang M, Zhang L, Windhofer F et al. DNA Igase II as a candidate component of backup pathways of nonhomologous end joining. Cancer Res 2005; 65: 4020–4030.
36. Brunet E, Simsek O, Tomishima M, DeFelver R, Choi YM, Gregory P et al. Chromosomal translocations induced at specified loci in human stem cells. Proc Natl Acad Sci USA 2009; 106: 20527–20532.
37. Nambiar M, Raghavan SC. Prevalence and analysis of t(14;18) and t(11;14) chromosomal translocations in healthy Indian population. Ann Hematol 2010; 89: 35–43.
38. Summers KE, Goff LK, Wilson AG, Gupta RK, Lister TA, Fitzgibbon J. Frequency of the Bcl-2/ IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol 2001; 19: 420–424.
39. Brassecco MS, Camparoto ML, Tone LG, Sakamoto-Hojo ET. Analysis of ETV6/RUNX1 fusions for evaluating the late effects of cancer therapy in ALL (acute lymphoblastic leukemia) cured patients. Cytoenetogen Genes Chromosome Res 2004; 104: 346–351.
40. Janz S, Potter M, Rabkin CS. Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals. Genes Chromosomes Cancer 2003; 36: 211–223.
41. Schuler F, Hirt C, Dolken G. Chromosomal translocation (t(14;18)) in healthy individuals. Semin Cancer Biol 2003; 13: 203–209.
42. Nambiar M, Raghavan SC. Chromosomal translocations among the healthy human population; implications in oncogenesis. Cell Mol Life Sci 2013; 70: 1381–1392.
43. Delbaere J, Zhou Y, Tsoi MS, Kuhlner J, Carney JP, Paul TT et al. Mre11/Rad50/Nbs1 and DNA Igase I(α)/XRCC1 act together in an alternative non-homologous end joining pathway. J Biol Chem 2006; 281: 33845–33853.
44. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA Igase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004; 279: 55117–55126.
45. Kumar TS, Kari V, Choudhary B, Nambiar M, Akila TS, Raghavan SC. Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells. J Biol Chem 2010; 285: 32657–32670.
46. Nambiar M, Goldsmith G, Moorthy BT, Lieber MR, Joshi MV, Choudhary B et al. Formation of a G-quadruplex at the BCL2 major breakpoint region of the t(14;18) translocation in follicular lymphoma. Nucleic Acids Res 2011; 39: 936–948.
47. Sathees CR, Kari V, Choudhary B, Nambiar M, Akila TS, Raghavan SC. Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells. J Biol Chem 2010; 285: 32657–32670.
48. Nambiar M, Goldsmith G, Moorthy BT, Lieber MR, Joshi MV, Choudhary B et al. Formation of a G-quadruplex at the BCL2 major breakpoint region of the t(14;18) translocation in follicular lymphoma. Nucleic Acids Res 2011; 39: 936–948.
49. Sathees CR, Kari V, Choudhary B, Nambiar M, Akila TS, Raghavan SC. Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells. J Biol Chem 2010; 285: 32657–32670.
50. Nambiar M, Goldsmith G, Moorthy BT, Lieber MR, Joshi MV, Choudhary B et al. Formation of a G-quadruplex at the BCL2 major breakpoint region of the t(14;18) translocation in follicular lymphoma. Nucleic Acids Res 2011; 39: 936–948.
50. Kavitha CV, Nambar M, Ananda Kumar CS, Choudhary B, Muniyappa K, Rangappa KS et al. Novel derivatives of spirohydantoin induce growth inhibition followed by apoptosis in leukemia cells. Biochem Pharmacol 2009; 77: 348–363.

51. Chiruvella KK, Sebastian R, Sharma S, Karande AA, Choudhary B, Raghavan SC. Time-dependent predominance of nonhomologous DNA end-joining pathways during embryonic development in mice. J Mol Biol 2012; 417: 197–211.

52. Gunn A, Stark JM. I-SceI-based assays to examine distinct repair outcomes of mammalian chromosomal double strand breaks. Methods Mol Biol 2012; 920: 379–391.

53. Chiruvella KK, Kari V, Choudhary B, Nambar M, Ghanta RG, Raghavan SC. Methyl angolensate, a natural tetranortriterpenoid induces intrinsic apoptotic pathway in leukemic cells. FEBS Lett 2008; 582: 4066–4076.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)